Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05197270 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study sites: 25 to 26 Study description revised · Eligibility criteria expanded, about 2 wordsv12 Show 2 more changesShow less
    • Study description revised
    • Eligibility criteria expanded, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  2. Study sites: 24 to 25 Eligibility criteria expanded, about 472 words · Study description shortened, about 2 wordsv11 Show 2 more changesShow less
    • Eligibility criteria expanded, about 472 words
    • Study description shortened, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  3. Re-verified, no change to tracked fieldsv10
  4. Primary completion date: Nov 2025 to Mar 2027 Completion date: Nov 2026 to Jan 2031 · Eligibility criteria expanded, about 104 words · Secondary endpoints: 5 to 6 · 3 morev9 Show 6 more changesShow less
    • Completion date: Nov 2026 to Jan 2031
    • Eligibility criteria expanded, about 104 words
    • Secondary endpoints: 5 to 6
    • Study description expanded, about 80 words
    • Site details revised at 24 of 24 sites
    • Study arms: 8 to 10

    See this version in full on ClinicalTrials.gov ↗

  5. Primary completion date: Nov 2024 to Nov 2025 Enrollment target: 150 to 215 · Study sites: 26 to 24 · Completion date: Nov 2025 to Nov 2026 · 1 morev8 Show 4 more changesShow less
    • Enrollment target: 150 to 215
    • Study sites: 26 to 24
    • Completion date: Nov 2025 to Nov 2026
    • Study arms: 7 to 8
Show 6 earlier versionsHide 6 earlier versions
  1. Site details revised at 1 of 26 sitesv7
  2. Enrollment target: 65 to 150 Primary completion date: May 30, 2026 to Nov 2024 · Study sites: 24 to 26 · Completion date: Sep 30, 2026 to Nov 2025 · 3 morev6 Show 6 more changesShow less
    • Primary completion date: May 30, 2026 to Nov 2024
    • Study sites: 24 to 26
    • Completion date: Sep 30, 2026 to Nov 2025
    • Eligibility criteria shortened, about 14 words
    • Study description expanded, about 32 words
    • Study arms: 4 to 7

    See this version in full on ClinicalTrials.gov ↗

  3. Study sites: 14 to 24v5
  4. Study sites: 10 to 14v4
  5. Study sites: 6 to 10v3
  6. Study sites: 4 to 6v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Phase 1/2 dose-escalation and randomized, controlled, masked expansion trial in adults with wet AMD undergoing active anti-VEGF treatment. Substudies will evaluate the safety and tolerability of 4D-150 contralateral eye dosing and characterize vector shedding.
Trial Details
NCT Number NCT05197270
Lead Sponsor 4D Molecular Therapeutics
Conditions Neovascular (Wet) Age-Related Macular Degeneration
Enrollment 215 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov